Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Diamondback Drugs of Delaware, LLC
483
•Diamondback Drugs of Delaware, LLC•May 17, 2013

Diamondback Drugs of Delaware, LLC – FDA 483, May 17, 2013

Record Details

The FDA Form 483 details significant deficiencies at a facility producing sterile drug products, including Buprenorphine HCl vials.

**Environmental Monitoring and Aseptic Processing Deficiencies:** * **Lack of Active Monitoring:** No active viable or non-viable particulate air monitoring during aseptic processing in ISO 5 hoods or ISO 7 cleanrooms. Monitoring is only conducted statically by an outside contractor. * **Pressure Differential Monitoring:** No active monitoring of cleanroom pressure differentials during processing; gauges are absent or unread. * **Personnel Monitoring:** No post-shift monitoring of personnel gloves or arms in ISO 5 hoods. * **Insufficient Frequency:** Environmental monitoring of ISO 5 hood and ISO 7 cleanroom surfaces is conducted infrequently by an outside contractor.

**Sterilization Process Validation and Control Issues:** * **Inadequate Media Fills:** Media fills do not represent actual production conditions (duration, batch size, environmental details). * **Out-of-Specification Certification:** An ante-room exceeded non-viable particulate specifications during certification but was still certified without re-sampling. * **Lack of Smoke Studies:** No recording of smoke studies for ISO 5 hoods, and no smoke studies performed in ISO 7 cleanrooms. * **Sterilization Process Validation:** No (b)(4) testing for the sterilizing step of drug products like Buprenorphine HCl. * **Component Ster

Company
Diamondback Drugs of Delaware, LLC
Inspection date
May 17, 2013
Product type
Drugs
Office
Los Angeles District Office
Person
  • Joey V. Quitania (Public Affairs Specialist)
View Company Profile

ID · debbc101-bb5d-4076-874e-54e0ec9a820b

Violation Codes3
21 CFR 21021 CFR 21121 CFR 801(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Diamondback Drugs of Delaware, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.